Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:trastuzumab
|
| gptkbp:activities |
gptkb:fragrance
|
| gptkbp:appointed_by |
combination therapy
oral tablet |
| gptkbp:approves |
gptkb:1998
gptkb:FDA |
| gptkbp:brand |
gptkb:Xeloda
|
| gptkbp:class |
pyrimidine analog
|
| gptkbp:clinical_trial |
Phase III
neoadjuvant therapy palliative treatment |
| gptkbp:contraindication |
pregnancy
breastfeeding severe renal impairment |
| gptkbp:counseling_services |
take with food
stay hydrated avoid pregnancy during treatment report severe side effects follow-up appointments are important |
| gptkbp:developed_by |
gptkb:Roche
|
| gptkbp:dosage_form |
twice daily
1250 mg/m2 |
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
capecitabine
|
| gptkbp:ingredients |
C15 H22 N2 O6 S
|
| gptkbp:interacts_with |
gptkb:phenytoin
gptkb:leucovorin gptkb:warfarin |
| gptkbp:is_atype_of |
L01 B C06
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count renal function tests |
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:lifespan |
1.5 hours
|
| gptkbp:metabolism |
gptkb:5-fluorouracil
|
| gptkbp:pharmacokinetics |
oral bioavailability
inhibits DNA synthesis peak plasma concentration time to peak concentration |
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea vomiting diarrhea thrombocytopenia stomatitis hand-foot syndrome mucositis |
| gptkbp:targets |
metastatic cancer
adjuvant therapy |
| gptkbp:traded_on |
gptkb:Xeloda
|
| gptkbp:type_of |
154361-50-9
|